(Total Views: 357)
Posted On: 05/07/2025 6:52:30 PM
Post# of 154635
For pembrolizumab + standard chemotherapy and sacituzumab govitecan (ASCENT) there are only 2 years of data presented versus the French ESME program had 3 years. Would there be a reason the first two dont have 3 year data?
(1)
(0)
The fault-finder will find faults even in paradise. -Henry David Thoreau
